[Exclusive] ImmunMed Pursues KOSDAQ Tech-Special Listing... Conditions Met

[Asia Economy Reporter Lee Seon-ae] Immuned, known as a developer of COVID-19 treatments, is accelerating its initial public offering (IPO) process.

Immuned stated, "We received the technology evaluation results for the KOSDAQ special technical listing on the 23rd, and the results met the conditions for special listing," adding, "We will make every effort to ensure that the upcoming listing preparation procedures proceed smoothly."

This achievement comes about a year after the IPO schedule was canceled due to not obtaining an excellent grade in last year's technology evaluation. As the planned Phase 2 clinical trials have been sequentially initiated domestically and internationally, it is interpreted that the technology evaluation was smoothly passed this time.

Meanwhile, although the IPO schedule was delayed by about a year, Immuned's valuation soared during that period. The corporate value, which was around 150 billion KRW at the time of investment just before the IPO in 2019, increased by more than 100 billion KRW to 250 billion KRW as of March this year. The listing is being led by Mirae Asset Daewoo and Daishin Securities.

This content was produced with the assistance of AI translation services.